Skip to content
2000
image of Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development
file format pdf download PDF

Abstract

This review outlines the Gates Foundation’s investments in support of global efforts dedicated to the research and development of a safe, highly effective, prophylactic HIV vaccine. Our current Collaboration for AIDS Vaccine Discovery (CAVD) portfolio encompasses a wide range of initiatives, including projects aimed at eliciting broadly neutralizing antibodies, enhancing CD8 T cell responses, and, through central service facilities, developing innovative analytical tools and animal models to assess immune responses. One central service facility also offers product development services to translate preclinical findings into clinical trials. Additionally, we are investing in platforms designed for the controlled release of HIV immunogens, simplifying complex vaccine regimens. Our ultimate objective is to develop a highly efficacious, safe, and durable vaccine that ensures broad access, uptake, and affordability. Furthermore, we emphasize the critical importance of fostering global partnerships, with a focus on supporting research capacity in low- and middle-income countries. By making intentional investments, we aim to stimulate sustainable research and development in the regions most affected by the HIV epidemic.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X364991250710044947
2025-07-28
2025-12-05

  • From This Site

    /content/journals/chr/10.2174/011570162X364991250710044947
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/chr/10.2174/011570162X364991250710044947/BMS-CHIVR-2024-HT10-6091-9.html?itemId=/content/journals/chr/10.2174/011570162X364991250710044947&mimeType=html&fmt=ahah

References

  1. Murray C.J.L. GBD 2021 Collaborators Findings from the global burden of disease study 2021. Lancet 2024 403 10440 2259 2262 10.1016/S0140‑6736(24)00769‑4 38762327
    [Google Scholar]
  2. UNAIDS Global AIDS Update – Executive Summary. 2024 Available from:
  3. Incidence rates until 2030 IHME projections, using IHME’s “better” and “worse” scenarios. Respective negative growth rates projected until 2050. 2023
    [Google Scholar]
  4. Nkolola J.P. Barouch D.H. Prophylactic HIV-1 vaccine trials: Past, present, and future. Lancet HIV 2024 11 2 e117 e124 10.1016/S2352‑3018(23)00264‑3 38141639
    [Google Scholar]
  5. Johnston MI Scarlatti G Pitisutthithum P Bekker LG HIV vaccines: Progress and promise. J. Int. AIDS Soc. 2021 24 Suppl 7 25828
    [Google Scholar]
  6. Bershteyn A. Klein D.J. Wenger E. Eckhoff P.A. Description of the EMOD-HIV Model v0.7. arXiv 2012 1206.3720
    [Google Scholar]
  7. Stover J. Hallett T.B. Wu Z. Warren M. Gopalappa C. Pretorius C. Ghys P.D. Montaner J. Schwartländer B. New Prevention Technology Study Group How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. PLoS One 2014 9 11 111956 10.1371/journal.pone.0111956 25372770
    [Google Scholar]
  8. Godfrey-Faussett P. Frescura L. Abdool Karim Q. Clayton M. Ghys P.D. on behalf of the 2025 prevention targets working group HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention. PLoS Med. 2022 19 9 1004102 10.1371/journal.pmed.1004102 36156593
    [Google Scholar]
  9. Rautenbach S.P. Whittles L.K. Meyer-Rath G. Jamieson L. Chidarikire T. Johnson L.F. Imai-Eaton J.W. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: A mathematical modelling study. Lancet Public Health 2024 9 4 e218 e230 10.1016/S2468‑2667(24)00020‑3 38553141
    [Google Scholar]
  10. Henderson M. Perspectives and preferences regarding long-acting injectable cabotegravir for HIV prevention among pre-exposure prophylaxis (PREP) providers: A global survey and in-depth interviews. Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention. Geneva: World Health Organization 2022
    [Google Scholar]
  11. Venter W.D.F. Gandhi M. Sokhela S. Sikwese K. Bygrave H. Gama L.D. Mphothulo N. Jamieson L. Siedner M.J. Pozniak A.L. Rojo P. Baptiste S.L. Wambui J. Meyer-Rath G. Honermann B. Warren M. Bekker L.G. Sinxadi P. Collins S. Burry J. Möller K. Clayden P. Owen A. Hill A. The long wait for long-acting HIV prevention and treatment formulations. Lancet HIV 2024 11 10 e711 e716 10.1016/S2352‑3018(24)00173‑5 39159655
    [Google Scholar]
  12. Parikh U.M. Koss C.A. Mellors J.W. Long-acting injectable cabotegravir for HIV prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance? Curr. HIV/AIDS Rep. 2022 19 5 384 393 10.1007/s11904‑022‑00616‑y 36112336
    [Google Scholar]
  13. Golub S.A. PrEP stigma: Implicit and explicit drivers of disparity. Curr. HIV/AIDS Rep. 2018 15 2 190 197 10.1007/s11904‑018‑0385‑0 29460223
    [Google Scholar]
  14. Burton D.R. Advancing an HIV vaccine; Advancing vaccinology. Nat. Rev. Immunol. 2019 19 2 77 78 10.1038/s41577‑018‑0103‑6 30560910
    [Google Scholar]
  15. Kelsoe G. Haynes B.F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 2017 275 1 79 88 10.1111/imr.12508 28133807
    [Google Scholar]
  16. Derking R Sanders RW Structure-guided envelope trimer design in HIV-1 vaccine development: A narrative review. J. Int. AIDS Soc. 2021 24 Suppl 7 25797
    [Google Scholar]
  17. Wiehe K. Bradley T. Meyerhoff R.R. Hart C. Williams W.B. Easterhoff D. Faison W.J. Kepler T.B. Saunders K.O. Alam S.M. Bonsignori M. Haynes B.F. Functional relevance of improbable antibody mutations for HIV broadly neutralizing antibody development. Cell Host Microbe 2018 23 6 759 765.e6 10.1016/j.chom.2018.04.018 29861171
    [Google Scholar]
  18. Williams WB Wiehe K Saunders KO Haynes BF Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. J. Int. AIDS Soc. 2021 24 Suppl 7 25831
    [Google Scholar]
  19. Vandegraaff N. Kumar R. Burrell C.J. Li P. Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA. J. Virol. 2001 75 22 11253 11260 10.1128/JVI.75.22.11253‑11260.2001 11602768
    [Google Scholar]
  20. Wei X. Decker J.M. Wang S. Hui H. Kappes J.C. Wu X. Salazar-Gonzalez J.F. Salazar M.G. Kilby J.M. Saag M.S. Komarova N.L. Nowak M.A. Hahn B.H. Kwong P.D. Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003 422 6929 307 312 10.1038/nature01470 12646921
    [Google Scholar]
  21. Medina-Ramírez M. Sanders R.W. Klasse P.J. Targeting B-cell germlines and focusing affinity maturation: The next hurdles in HIV-1-vaccine development? Expert Rev. Vaccines 2014 13 4 449 452 10.1586/14760584.2014.894469 24606603
    [Google Scholar]
  22. Escolano A. Steichen J.M. Dosenovic P. Kulp D.W. Golijanin J. Sok D. Freund N.T. Gitlin A.D. Oliveira T. Araki T. Lowe S. Chen S.T. Heinemann J. Yao K.H. Georgeson E. Saye-Francisco K.L. Gazumyan A. Adachi Y. Kubitz M. Burton D.R. Schief W.R. Nussenzweig M.C. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in ig knockin mice. Cell 2016 166 6 1445 1458.e12 10.1016/j.cell.2016.07.030 27610569
    [Google Scholar]
  23. Stamatatos L. Pancera M. McGuire A.T. Germline‐targeting immunogens. Immunol. Rev. 2017 275 1 203 216 10.1111/imr.12483 28133796
    [Google Scholar]
  24. Steichen J.M. Lin Y.C. Havenar-Daughton C. Pecetta S. Ozorowski G. Willis J.R. Toy L. Sok D. Liguori A. Kratochvil S. Torres J.L. Kalyuzhniy O. Melzi E. Kulp D.W. Raemisch S. Hu X. Bernard S.M. Georgeson E. Phelps N. Adachi Y. Kubitz M. Landais E. Umotoy J. Robinson A. Briney B. Wilson I.A. Burton D.R. Ward A.B. Crotty S. Batista F.D. Schief W.R. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science 2019 366 6470 eaax4380 10.1126/science.aax4380 31672916
    [Google Scholar]
  25. Wang X. Cottrell C.A. Hu X. Ray R. Bottermann M. Villavicencio P.M. Yan Y. Xie Z. Warner J.E. Ellis-Pugh J.R. Kalyuzhniy O. Liguori A. Willis J.R. Menis S. Rämisch S. Eskandarzadeh S. Kubitz M. Tingle R. Phelps N. Groschel B. Himansu S. Carfi A. Kirsch K.H. Weldon S.R. Nair U. Schief W.R. Batista F.D. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models. Sci. Immunol. 2024 9 95 eadn0622 10.1126/sciimmunol.adn0622 38753808
    [Google Scholar]
  26. Cottrell C.A. Hu X. Lee J.H. Skog P. Luo S. Flynn C.T. McKenney K.R. Hurtado J. Kalyuzhniy O. Liguori A. Willis J.R. Landais E. Raemisch S. Chen X. Baboo S. Himansu S. Diedrich J.K. Duan H. Cheng C. Schiffner T. Bader D.L.V. Kulp D.W. Tingle R. Georgeson E. Eskandarzadeh S. Alavi N. Lu D. Sincomb T. Kubitz M. Mullen T.M. Yates J.R. III Paulson J.C. Mascola J.R. Alt F.W. Briney B. Sok D. Schief W.R. Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. Sci. Transl. Med. 2024 16 748 eadn0223 10.1126/scitranslmed.adn0223 38753806
    [Google Scholar]
  27. Leggat D.J. Cohen K.W. Willis J.R. Fulp W.J. deCamp A.C. Kalyuzhniy O. Cottrell C.A. Menis S. Finak G. Ballweber-Fleming L. Srikanth A. Plyler J.R. Schiffner T. Liguori A. Rahaman F. Lombardo A. Philiponis V. Whaley R.E. Seese A. Brand J. Ruppel A.M. Hoyland W. Yates N.L. Williams L.D. Greene K. Gao H. Mahoney C.R. Corcoran M.M. Cagigi A. Taylor A. Brown D.M. Ambrozak D.R. Sincomb T. Hu X. Tingle R. Georgeson E. Eskandarzadeh S. Alavi N. Lu D. Mullen T.M. Kubitz M. Groschel B. Maenza J. Kolokythas O. Khati N. Bethony J. Crotty S. Roederer M. Karlsson Hedestam G.B. Tomaras G.D. Montefiori D. Diemert D. Koup R.A. Laufer D.S. McElrath M.J. McDermott A.B. Schief W.R. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 2022 378 6623 eadd6502 10.1126/science.add6502 36454825
    [Google Scholar]
  28. Cohen J. Puzzling skin side effects stymie advance of promising HIV vaccine. Science 2023 383 1044
    [Google Scholar]
  29. Xie Z. Lin Y.C. Steichen J.M. Ozorowski G. Kratochvil S. Ray R. Torres J.L. Liguori A. Kalyuzhniy O. Wang X. Warner J.E. Weldon S.R. Dale G.A. Kirsch K.H. Nair U. Baboo S. Georgeson E. Adachi Y. Kubitz M. Jackson A.M. Richey S.T. Volk R.M. Lee J.H. Diedrich J.K. Prum T. Falcone S. Himansu S. Carfi A. Yates J.R. III Paulson J.C. Sok D. Ward A.B. Schief W.R. Batista F.D. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 2024 384 6697 eadk0582 10.1126/science.adk0582 38753770
    [Google Scholar]
  30. Melzi E. Willis J.R. Ma K.M. Lin Y.C. Kratochvil S. Berndsen Z.T. Landais E.A. Kalyuzhniy O. Nair U. Warner J. Steichen J.M. Kalyuzhniy A. Le A. Pecetta S. Perez M. Kirsch K. Weldon S.R. Falcone S. Himansu S. Carfi A. Sok D. Ward A.B. Schief W.R. Batista F.D. Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice. Immunity 2022 55 11 2168 2186.e6 10.1016/j.immuni.2022.09.003 36179690
    [Google Scholar]
  31. Schiffner T. Phung I. Ray R. Irimia A. Tian M. Swanson O. Lee J.H. Lee C.C.D. Marina-Zárate E. Cho S.Y. Huang J. Ozorowski G. Skog P.D. Serra A.M. Rantalainen K. Allen J.D. Baboo S. Rodriguez O.L. Himansu S. Zhou J. Hurtado J. Flynn C.T. McKenney K. Havenar-Daughton C. Saha S. Shields K. Schultze S. Smith M.L. Liang C.H. Toy L. Pecetta S. Lin Y.C. Willis J.R. Sesterhenn F. Kulp D.W. Hu X. Cottrell C.A. Zhou X. Ruiz J. Wang X. Nair U. Kirsch K.H. Cheng H.L. Davis J. Kalyuzhniy O. Liguori A. Diedrich J.K. Ngo J.T. Lewis V. Phelps N. Tingle R.D. Spencer S. Georgeson E. Adachi Y. Kubitz M. Eskandarzadeh S. Elsliger M.A. Amara R.R. Landais E. Briney B. Burton D.R. Carnathan D.G. Silvestri G. Watson C.T. Yates J.R. III Paulson J.C. Crispin M. Grigoryan G. Ward A.B. Sok D. Alt F.W. Wilson I.A. Batista F.D. Crotty S. Schief W.R. Vaccination induces broadly neutralizing antibody precursors to HIV gp41. Nat. Immunol. 2024 25 6 1073 1082 10.1038/s41590‑024‑01833‑w 38816615
    [Google Scholar]
  32. Steichen J.M. Phung I. Salcedo E. Ozorowski G. Willis J.R. Baboo S. Liguori A. Cottrell C.A. Torres J.L. Madden P.J. Ma K.M. Sutton H.J. Lee J.H. Kalyuzhniy O. Allen J.D. Rodriguez O.L. Adachi Y. Mullen T.M. Georgeson E. Kubitz M. Burns A. Barman S. Mopuri R. Metz A. Altheide T.K. Diedrich J.K. Saha S. Shields K. Schultze S.E. Smith M.L. Schiffner T. Burton D.R. Watson C.T. Bosinger S.E. Crispin M. Yates J.R. III Paulson J.C. Ward A.B. Sok D. Crotty S. Schief W.R. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates. Science 2024 384 6697 eadj8321 10.1126/science.adj8321 38753769
    [Google Scholar]
  33. Medina-Ramírez M. Garces F. Escolano A. Skog P. de Taeye S.W. Del Moral-Sanchez I. McGuire A.T. Yasmeen A. Behrens A.J. Ozorowski G. van den Kerkhof T.L.G.M. Freund N.T. Dosenovic P. Hua Y. Gitlin A.D. Cupo A. van der Woude P. Golabek M. Sliepen K. Blane T. Kootstra N. van Breemen M.J. Pritchard L.K. Stanfield R.L. Crispin M. Ward A.B. Stamatatos L. Klasse P.J. Moore J.P. Nemazee D. Nussenzweig M.C. Wilson I.A. Sanders R.W. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 2017 214 9 2573 2590 10.1084/jem.20161160 28847869
    [Google Scholar]
  34. Caniels T.G. Medina-Ramìrez M. Zhang S. Kratochvil S. Xian Y. Koo J.H. Derking R. Samsel J. van Schooten J. Pecetta S. Lamperti E. Yuan M. Carrasco M.R. del Moral Sánchez I. Allen J.D. Bouhuijs J.H. Yasmeen A. Ketas T.J. Snitselaar J.L. Bijl T.P.L. Martin I.C. Torres J.L. Cupo A. Shirreff L. Rogers K. Mason R.D. Roederer M. Greene K.M. Gao H. Silva C.M. Baken I.J.L. Tian M. Alt F.W. Pulendran B. Seaman M.S. Crispin M. van Gils M.J. Montefiori D.C. McDermott A.B. Villinger F.J. Koup R.A. Moore J.P. Klasse P.J. Ozorowski G. Batista F.D. Wilson I.A. Ward A.B. Sanders R.W. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Sci. Immunol. 2024 9 98 eadk9550 10.1126/sciimmunol.adk9550 39213338
    [Google Scholar]
  35. Caniels T.G. Medina-Ramírez M. Zhang J. Sarkar A. Kumar S. LaBranche A. Derking R. Allen J.D. Snitselaar J.L. Capella-Pujol J. Sánchez I.M. Yasmeen A. Diaz M. Aldon Y. Bijl T.P.L. Venkatayogi S. Martin Beem J.S. Newman A. Jiang C. Lee W.H. Pater M. Burger J.A. van Breemen M.J. de Taeye S.W. Rantalainen K. LaBranche C. Saunders K.O. Montefiori D. Ozorowski G. Ward A.B. Crispin M. Moore J.P. Klasse P.J. Haynes B.F. Wilson I.A. Wiehe K. Verkoczy L. Sanders R.W. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell Rep. Med. 2023 4 4 101003 10.1016/j.xcrm.2023.101003 37044090
    [Google Scholar]
  36. Straten Karlijn S.V.D. Safety Profile and Immunogenicity of a Phase I Clinical Trial Using Germline-Targeting Trimer GT1.1. CROI 2024
    [Google Scholar]
  37. del Moral-Sánchez I. Wee E.G. Xian Y. Lee W.H. Allen J.D. Torrents de la Peña A. Fróes Rocha R. Ferguson J. León A.N. Koekkoek S. Schermer E.E. Burger J.A. Kumar S. Zwolsman R. Brinkkemper M. Aartse A. Eggink D. Han J. Yuan M. Crispin M. Ozorowski G. Ward A.B. Wilson I.A. Hanke T. Sliepen K. Sanders R.W. Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. NPJ Vaccines 2024 9 1 74 10.1038/s41541‑024‑00862‑8 38582771
    [Google Scholar]
  38. Roark R.S. Li H. Williams W.B. Chug H. Mason R.D. Gorman J. Wang S. Lee F.H. Rando J. Bonsignori M. Hwang K.K. Saunders K.O. Wiehe K. Moody M.A. Hraber P.T. Wagh K. Giorgi E.E. Russell R.M. Bibollet-Ruche F. Liu W. Connell J. Smith A.G. DeVoto J. Murphy A.I. Smith J. Ding W. Zhao C. Chohan N. Okumura M. Rosario C. Ding Y. Lindemuth E. Bauer A.M. Bar K.J. Ambrozak D. Chao C.W. Chuang G.Y. Geng H. Lin B.C. Louder M.K. Nguyen R. Zhang B. Lewis M.G. Raymond D.D. Doria-Rose N.A. Schramm C.A. Douek D.C. Roederer M. Kepler T.B. Kelsoe G. Mascola J.R. Kwong P.D. Korber B.T. Harrison S.C. Haynes B.F. Hahn B.H. Shaw G.M. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science 2021 371 6525 eabd2638 10.1126/science.abd2638 33214287
    [Google Scholar]
  39. Haynes B.F. Kelsoe G. Harrison S.C. Kepler T.B. B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012 30 5 423 433 10.1038/nbt.2197 22565972
    [Google Scholar]
  40. Bonsignori M. Liao H.X. Gao F. Williams W.B. Alam S.M. Montefiori D.C. Haynes B.F. Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development. Immunol. Rev. 2017 275 1 145 160 10.1111/imr.12509 28133802
    [Google Scholar]
  41. Mu Z. Haynes B.F. Cain D.W. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. Curr. Opin. Virol. 2021 51 172 178 10.1016/j.coviro.2021.09.015 34742037
    [Google Scholar]
  42. Haynes B.F. Wiehe K. Borrow P. Saunders K.O. Korber B. Wagh K. McMichael A.J. Kelsoe G. Hahn B.H. Alt F. Shaw G.M. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023 23 3 142 158 10.1038/s41577‑022‑00753‑w 35962033
    [Google Scholar]
  43. Martin Beem J.S. Venkatayogi S. Haynes B.F. Wiehe K. ARMADiLLO: A web server for analyzing antibody mutation probabilities. Nucleic Acids Res. 2023 51 W1 W51 W56 10.1093/nar/gkad398 37260077
    [Google Scholar]
  44. Williams W.B. Alam S.M. Ofek G. Erdmann N. Montefiori D.C. Seaman M.S. Wagh K. Korber B. Edwards R.J. Mansouri K. Eaton A. Cain D.W. Martin M. Hwang J. Arus-Altuz A. Lu X. Cai F. Jamieson N. Parks R. Barr M. Foulger A. Anasti K. Patel P. Sammour S. Parsons R.J. Huang X. Lindenberger J. Fetics S. Janowska K. Niyongabo A. Janus B.M. Astavans A. Fox C.B. Mohanty I. Evangelous T. Chen Y. Berry M. Kirshner H. Van Itallie E. Saunders K.O. Wiehe K. Cohen K.W. McElrath M.J. Corey L. Acharya P. Walsh S.R. Baden L.R. Haynes B.F. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. Cell 2024 187 12 2919 2934.e20 10.1016/j.cell.2024.04.033 38761800
    [Google Scholar]
  45. Musunuri S. Weidenbacher P.A.B. Kim P.S. Bringing immunofocusing into focus. NPJ Vaccines 2024 9 1 11 10.1038/s41541‑023‑00792‑x 38195562
    [Google Scholar]
  46. Xu K. Acharya P. Kong R. Cheng C. Chuang G.Y. Liu K. Louder M.K. O’Dell S. Rawi R. Sastry M. Shen C.H. Zhang B. Zhou T. Asokan M. Bailer R.T. Chambers M. Chen X. Choi C.W. Dandey V.P. Doria-Rose N.A. Druz A. Eng E.T. Farney S.K. Foulds K.E. Geng H. Georgiev I.S. Gorman J. Hill K.R. Jafari A.J. Kwon Y.D. Lai Y.T. Lemmin T. McKee K. Ohr T.Y. Ou L. Peng D. Rowshan A.P. Sheng Z. Todd J.P. Tsybovsky Y. Viox E.G. Wang Y. Wei H. Yang Y. Zhou A.F. Chen R. Yang L. Scorpio D.G. McDermott A.B. Shapiro L. Carragher B. Potter C.S. Mascola J.R. Kwong P.D. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 2018 24 6 857 867 10.1038/s41591‑018‑0042‑6 29867235
    [Google Scholar]
  47. Bricault C.A. Kovacs J.M. Nkolola J.P. Yusim K. Giorgi E.E. Shields J.L. Perry J. Lavine C.L. Cheung A. Ellingson-Strouss K. Rademeyer C. Gray G.E. Williamson C. Stamatatos L. Seaman M.S. Korber B.T. Chen B. Barouch D.H. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J. Virol. 2015 89 5 2507 2519 10.1128/JVI.03331‑14 25540368
    [Google Scholar]
  48. Bricault C.A. Yusim K. Seaman M.S. Yoon H. Theiler J. Giorgi E.E. Wagh K. Theiler M. Hraber P. Macke J.P. Kreider E.F. Learn G.H. Hahn B.H. Scheid J.F. Kovacs J.M. Shields J.L. Lavine C.L. Ghantous F. Rist M. Bayne M.G. Neubauer G.H. McMahan K. Peng H. Chéneau C. Jones J.J. Zeng J. Ochsenbauer C. Nkolola J.P. Stephenson K.E. Chen B. Gnanakaran S. Bonsignori M. Williams L.D. Haynes B.F. Doria-Rose N. Mascola J.R. Montefiori D.C. Barouch D.H. Korber B. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019 25 1 59 72.e8 10.1016/j.chom.2018.12.001 30629920
    [Google Scholar]
  49. Escolano A Gristick HB Gautam R DeLaitsch AT Abernathy ME Yang Z Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Sci. Transl. Med. 2021 13 621 eabk1533
    [Google Scholar]
  50. Gristick H.B. Hartweger H. Loewe M. van Schooten J. Ramos V. Oliveira T.Y. Nishimura Y. Koranda N.S. Wall A. Yao K.H. Poston D. Gazumyan A. Wiatr M. Horning M. Keeffe J.R. Hoffmann M.A.G. Yang Z. Abernathy M.E. Dam K.M.A. Gao H. Gnanapragasam P.N.P. Kakutani L.M. Pavlovitch-Bedzyk A.J. Seaman M.S. Howarth M. McGuire A.T. Stamatatos L. Martin M.A. West A.P. Jr Nussenzweig M.C. Bjorkman P.J. CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals. Sci. Immunol. 2023 8 80 eade6364 10.1126/sciimmunol.ade6364 36763635
    [Google Scholar]
  51. Zhang P. Narayanan E. Liu Q. Tsybovsky Y. Boswell K. Ding S. Hu Z. Follmann D. Lin Y. Miao H. Schmeisser H. Rogers D. Falcone S. Elbashir S.M. Presnyak V. Bahl K. Prabhakaran M. Chen X. Sarfo E.K. Ambrozak D.R. Gautam R. Martin M.A. Swerczek J. Herbert R. Weiss D. Misamore J. Ciaramella G. Himansu S. Stewart-Jones G. McDermott A. Koup R.A. Mascola J.R. Finzi A. Carfi A. Fauci A.S. Lusso P. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 2021 27 12 2234 2245 10.1038/s41591‑021‑01574‑5 34887575
    [Google Scholar]
  52. Bianchi M. Turner H.L. Nogal B. Cottrell C.A. Oyen D. Pauthner M. Bastidas R. Nedellec R. McCoy L.E. Wilson I.A. Burton D.R. Ward A.B. Hangartner L. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity 2018 49 2 288 300.e8 10.1016/j.immuni.2018.07.009 30097292
    [Google Scholar]
  53. Antanasijevic A. Sewall L.M. Cottrell C.A. Carnathan D.G. Jimenez L.E. Ngo J.T. Silverman J.B. Groschel B. Georgeson E. Bhiman J. Bastidas R. LaBranche C. Allen J.D. Copps J. Perrett H.R. Rantalainen K. Cannac F. Yang Y.R. de la Peña A.T. Rocha R.F. Berndsen Z.T. Baker D. King N.P. Sanders R.W. Moore J.P. Crotty S. Crispin M. Montefiori D.C. Burton D.R. Schief W.R. Silvestri G. Ward A.B. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat. Commun. 2021 12 1 4817 10.1038/s41467‑021‑25087‑4 34376662
    [Google Scholar]
  54. Lin Y.C. Pecetta S. Steichen J.M. Kratochvil S. Melzi E. Arnold J. Dougan S.K. Wu L. Kirsch K.H. Nair U. Schief W.R. Batista F.D. One‐step CRISPR /Cas9 method for the rapid generation of human antibody heavy chain knock‐in mice. EMBO J. 2018 37 18 99243 10.15252/embj.201899243 30087111
    [Google Scholar]
  55. Luo S. Jing C. Ye A.Y. Kratochvil S. Cottrell C.A. Koo J.H. Chapdelaine Williams A. Francisco L.V. Batra H. Lamperti E. Kalyuzhniy O. Zhang Y. Barbieri A. Manis J.P. Haynes B.F. Schief W.R. Batista F.D. Tian M. Alt F.W. Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors. Proc. Natl. Acad. Sci. USA 2023 120 1 2217883120 10.1073/pnas.2217883120 36574685
    [Google Scholar]
  56. Martin T.M. Robinson S.T. Huang Y. Discovery medicine – the HVTN’s iterative approach to developing an HIV-1 broadly neutralizing vaccine. Curr. Opin. HIV AIDS 2023 18 6 290 299 10.1097/COH.0000000000000821 37712873
    [Google Scholar]
  57. Prudden H. Tatoud R. Slack C. Shattock R. Anklesaria P. Bekker L.G. Buchbinder S. Experimental medicine for HIV vaccine research and development. Vaccines 2023 11 5 970 10.3390/vaccines11050970 37243074
    [Google Scholar]
  58. Corey L. Gilbert P.B. Juraska M. Montefiori D.C. Morris L. Karuna S.T. Edupuganti S. Mgodi N.M. deCamp A.C. Rudnicki E. Huang Y. Gonzales P. Cabello R. Orrell C. Lama J.R. Laher F. Lazarus E.M. Sanchez J. Frank I. Hinojosa J. Sobieszczyk M.E. Marshall K.E. Mukwekwerere P.G. Makhema J. Baden L.R. Mullins J.I. Williamson C. Hural J. McElrath M.J. Bentley C. Takuva S. Gomez Lorenzo M.M. Burns D.N. Espy N. Randhawa A.K. Kochar N. Piwowar-Manning E. Donnell D.J. Sista N. Andrew P. Kublin J.G. Gray G. Ledgerwood J.E. Mascola J.R. Cohen M.S. HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 2021 384 11 1003 1014 10.1056/NEJMoa2031738 33730454
    [Google Scholar]
  59. Hahn W.O. Parks K.R. Shen M. Ozorowski G. Janes H. Ballweber-Fleming L. Woodward Davis A.S. Duplessis C. Tomai M. Dey A.K. Sagawa Z.K. De Rosa S.C. Seese A. Kallur Siddaramaiah L. Stamatatos L. Lee W.H. Sewall L.M. Karlinsey D. Turner H.L. Rubin V. Furth S. MacPhee K. Duff M. Corey L. Keefer M.C. Edupuganti S. Frank I. Maenza J. Baden L.R. Hyrien O. Sanders R.W. Moore J.P. Ward A.B. Tomaras G.D. Montefiori D.C. Rouphael N. McElrath M.J. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. J. Exp. Med. 2024 221 10 20240604 10.1084/jem.20240604 39235529
    [Google Scholar]
  60. Yousefpour P. Zhang Y.J. Maiorino L. Melo M.B. Ramirez A M.A. Kumarapperuma S.C. Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP. bioRxiv 2024
    [Google Scholar]
  61. Tam H.H. Melo M.B. Kang M. Pelet J.M. Ruda V.M. Foley M.H. Hu J.K. Kumari S. Crampton J. Baldeon A.D. Sanders R.W. Moore J.P. Crotty S. Langer R. Anderson D.G. Chakraborty A.K. Irvine D.J. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl. Acad. Sci. USA 2016 113 43 E6639 E6648 10.1073/pnas.1606050113 27702895
    [Google Scholar]
  62. Cirelli K.M. Carnathan D.G. Nogal B. Martin J.T. Rodriguez O.L. Upadhyay A.A. Enemuo C.A. Gebru E.H. Choe Y. Viviano F. Nakao C. Pauthner M.G. Reiss S. Cottrell C.A. Smith M.L. Bastidas R. Gibson W. Wolabaugh A.N. Melo M.B. Cossette B. Kumar V. Patel N.B. Tokatlian T. Menis S. Kulp D.W. Burton D.R. Murrell B. Schief W.R. Bosinger S.E. Ward A.B. Watson C.T. Silvestri G. Irvine D.J. Crotty S. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell 2019 177 5 1153 1171.e28 10.1016/j.cell.2019.04.012 31080066
    [Google Scholar]
  63. Lee J.H. Sutton H.J. Cottrell C.A. Phung I. Ozorowski G. Sewall L.M. Nedellec R. Nakao C. Silva M. Richey S.T. Torres J.L. Lee W.H. Georgeson E. Kubitz M. Hodges S. Mullen T.M. Adachi Y. Cirelli K.M. Kaur A. Allers C. Fahlberg M. Grasperge B.F. Dufour J.P. Schiro F. Aye P.P. Kalyuzhniy O. Liguori A. Carnathan D.G. Silvestri G. Shen X. Montefiori D.C. Veazey R.S. Ward A.B. Hangartner L. Burton D.R. Irvine D.J. Schief W.R. Crotty S. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 2022 609 7929 998 1004 10.1038/s41586‑022‑05216‑9 36131022
    [Google Scholar]
  64. Kim J. Li W.A. Choi Y. Lewin S.A. Verbeke C.S. Dranoff G. Mooney D.J. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat. Biotechnol. 2015 33 1 64 72 10.1038/nbt.3071 25485616
    [Google Scholar]
  65. Correa S. Grosskopf A.K. Lopez Hernandez H. Chan D. Yu A.C. Stapleton L.M. Appel E.A. Translational applications of hydrogels. Chem. Rev. 2021 121 18 11385 11457 10.1021/acs.chemrev.0c01177 33938724
    [Google Scholar]
  66. Ou B.S. Saouaf O.M. Baillet J. Appel E.A. Sustained delivery approaches to improving adaptive immune responses. Adv. Drug Deliv. Rev. 2022 187 114401 10.1016/j.addr.2022.114401 35750115
    [Google Scholar]
  67. Tyagi P. Koskinen M. Mikkola J. Leino L. Schwarz A. Silica microparticles for sustained zero-order release of an anti-CD40L antibody. Drug Deliv. Transl. Res. 2018 8 2 368 374 10.1007/s13346‑017‑0408‑1 28752299
    [Google Scholar]
  68. Tyagi P. Koskinen M. Mikkola J. Sarkhel S. Leino L. Seth A. Madalli S. Will S. Howard V.G. Brant H. Corkill D. Injectable biodegradable silica depot: Two months of sustained release of the blood glucose lowering peptide, pramlintide. Pharmaceutics 2022 14 3 553 10.3390/pharmaceutics14030553 35335929
    [Google Scholar]
  69. Garcea R.L. Meinerz N.M. Dong M. Funke H. Ghazvini S. Randolph T.W. Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology. NPJ Vaccines 2020 5 1 45 10.1038/s41541‑020‑0195‑4 32528733
    [Google Scholar]
  70. Witeof A.E. Meinerz N.M. Walker K.D. Funke H.H. Garcea R.L. Randolph T.W. A single dose, thermostable, trivalent human papillomavirus vaccine formulated using atomic layer deposition. J. Pharm. Sci. 2023 112 8 2223 2229 10.1016/j.xphs.2023.02.007 36780987
    [Google Scholar]
  71. McHugh K.J. Nguyen T.D. Linehan A.R. Yang D. Behrens A.M. Rose S. Tochka Z.L. Tzeng S.Y. Norman J.J. Anselmo A.C. Xu X. Tomasic S. Taylor M.A. Lu J. Guarecuco R. Langer R. Jaklenec A. Fabrication of fillable microparticles and other complex 3D microstructures. Science 2017 357 6356 1138 1142 10.1126/science.aaf7447 28912242
    [Google Scholar]
  72. Guarecuco R. Lu J. McHugh K.J. Norman J.J. Thapa L.S. Lydon E. Langer R. Jaklenec A. Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination. Vaccine 2018 36 22 3161 3168 10.1016/j.vaccine.2017.05.094 28625520
    [Google Scholar]
  73. Tran K.T.M. Gavitt T.D. Farrell N.J. Curry E.J. Mara A.B. Patel A. Brown L. Kilpatrick S. Piotrowska R. Mishra N. Szczepanek S.M. Nguyen T.D. Transdermal microneedles for the programmable burst release of multiple vaccine payloads. Nat. Biomed. Eng. 2020 5 9 998 1007 10.1038/s41551‑020‑00650‑4 33230304
    [Google Scholar]
  74. Werner J.M. Abdalla A. Gara N. Ghany M.G. Rehermann B. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013 145 5 1026 1034 10.1053/j.gastro.2013.07.044 23916846
    [Google Scholar]
  75. White M.T. Bejon P. Olotu A. Griffin J.T. Riley E.M. Kester K.E. Ockenhouse C.F. Ghani A.C. The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection. PLoS One 2013 8 4 61395 10.1371/journal.pone.0061395 23613845
    [Google Scholar]
  76. Kazmin D. Nakaya H.I. Lee E.K. Johnson M.J. van der Most R. van den Berg R.A. Ballou W.R. Jongert E. Wille-Reece U. Ockenhouse C. Aderem A. Zak D.E. Sadoff J. Hendriks J. Wrammert J. Ahmed R. Pulendran B. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc. Natl. Acad. Sci. USA 2017 114 9 2425 2430 10.1073/pnas.1621489114 28193898
    [Google Scholar]
  77. Su B. Dispinseri S. Iannone V. Zhang T. Wu H. Carapito R. Bahram S. Scarlatti G. Moog C. Update on Fc-mediated antibody functions against HIV-1 beyond neutralization. Front. Immunol. 2019 10 2968 10.3389/fimmu.2019.02968 31921207
    [Google Scholar]
  78. Phelps M. Balazs A.B. Contribution to HIV prevention and treatment by antibody-mediated effector function and advances in broadly neutralizing antibody delivery by vectored immunoprophylaxis. Front. Immunol. 2021 12 734304 10.3389/fimmu.2021.734304 34603314
    [Google Scholar]
  79. Ndhlovu Z.M. Chibnik L.B. Proudfoot J. Vine S. McMullen A. Cesa K. Porichis F. Jones R.B. Alvino D.M. Hart M.G. Stampouloglou E. Piechocka-Trocha A. Kadie C. Pereyra F. Heckerman D. De Jager P.L. Walker B.D. Kaufmann D.E. High-dimensional immunomonitoring models of HIV-1–specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood 2013 121 5 801 811 10.1182/blood‑2012‑06‑436295 23233659
    [Google Scholar]
  80. Collins D.R. Gaiha G.D. Walker B.D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 2020 20 8 471 482 10.1038/s41577‑020‑0274‑9 32051540
    [Google Scholar]
  81. Bansal A. Gehre M.N. Qin K. Sterrett S. Ali A. Dang Y. Abraham S. Costanzo M.C. Venegas L.A. Tang J. Manjunath N. Brockman M.A. Yang O.O. Kan-Mitchell J. Goepfert P.A. HLA-E–restricted HIV-1–specific CD8+ T cell responses in natural infection. J. Clin. Invest. 2021 131 16 148979 10.1172/JCI148979 34228645
    [Google Scholar]
  82. Arunachalam P.S. Charles T.P. Joag V. Bollimpelli V.S. Scott M.K.D. Wimmers F. Burton S.L. Labranche C.C. Petitdemange C. Gangadhara S. Styles T.M. Quarnstrom C.F. Walter K.A. Ketas T.J. Legere T. Jagadeesh Reddy P.B. Kasturi S.P. Tsai A. Yeung B.Z. Gupta S. Tomai M. Vasilakos J. Shaw G.M. Kang C.Y. Moore J.P. Subramaniam S. Khatri P. Montefiori D. Kozlowski P.A. Derdeyn C.A. Hunter E. Masopust D. Amara R.R. Pulendran B. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 2020 26 6 932 940 10.1038/s41591‑020‑0858‑8 32393800
    [Google Scholar]
  83. Hansen S.G. Ford J.C. Lewis M.S. Ventura A.B. Hughes C.M. Coyne-Johnson L. Whizin N. Oswald K. Shoemaker R. Swanson T. Legasse A.W. Chiuchiolo M.J. Parks C.L. Axthelm M.K. Nelson J.A. Jarvis M.A. Piatak M. Jr Lifson J.D. Picker L.J. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011 473 7348 523 527 10.1038/nature10003 21562493
    [Google Scholar]
  84. Picker L.J. Lifson J.D. Gale M. Jr Hansen S.G. Früh K. Programming cytomegalovirus as an HIV vaccine. Trends Immunol. 2023 44 4 287 304 10.1016/j.it.2023.02.001 36894436
    [Google Scholar]
  85. Hansen S.G. Hancock M.H. Malouli D. Marshall E.E. Hughes C.M. Randall K.T. Morrow D. Ford J.C. Gilbride R.M. Selseth A.N. Trethewy R.E. Bishop L.M. Oswald K. Shoemaker R. Berkemeier B. Bosche W.J. Hull M. Silipino L. Nekorchuk M. Busman-Sahay K. Estes J.D. Axthelm M.K. Smedley J. Shao D. Edlefsen P.T. Lifson J.D. Früh K. Nelson J.A. Picker L.J. Myeloid cell tropism enables MHC-E–restricted CD8 + T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. Sci. Immunol. 2022 7 72 eabn9301 10.1126/sciimmunol.abn9301 35714200
    [Google Scholar]
  86. Barrenäs F. Hansen S.G. Law L. Driscoll C. Green R.R. Smith E. Chang J. Golez I. Urion T. Peng X. Whitmore L. Newhouse D. Hughes C.M. Morrow D. Randall K.T. Selseth A.N. Ford J.C. Gilbride R.M. Randall B.E. Ainslie E. Oswald K. Shoemaker R. Fast R. Bosche W.J. Axthelm M.K. Fukazawa Y. Pavlakis G.N. Felber B.K. Fourati S. Sekaly R.P. Lifson J.D. Komorowski J. Kosmider E. Shao D. Song W. Edlefsen P.T. Picker L.J. Gale M. Jr Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy. PLoS Pathog. 2021 17 7 1009278 10.1371/journal.ppat.1009278 34228762
    [Google Scholar]
  87. Malouli D. Gilbride R.M. Wu H.L. Hwang J.M. Maier N. Hughes C.M. Newhouse D. Morrow D. Ventura A.B. Law L. Tisoncik-Go J. Whitmore L. Smith E. Golez I. Chang J. Reed J.S. Waytashek C. Weber W. Taher H. Uebelhoer L.S. Womack J.L. McArdle M.R. Gao J. Papen C.R. Lifson J.D. Burwitz B.J. Axthelm M.K. Smedley J. Früh K. Gale M. Jr Picker L.J. Hansen S.G. Sacha J.B. Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell Host Microbe 2022 30 9 1207 1218.e7 10.1016/j.chom.2022.07.013 35981532
    [Google Scholar]
  88. Gaiha G.D. Rossin E.J. Urbach J. Landeros C. Collins D.R. Nwonu C. Muzhingi I. Anahtar M.N. Waring O.M. Piechocka-Trocha A. Waring M. Worrall D.P. Ghebremichael M.S. Newman R.M. Power K.A. Allen T.M. Chodosh J. Walker B.D. Structural topology defines protective CD8 + T cell epitopes in the HIV proteome. Science 2019 364 6439 480 484 10.1126/science.aav5095 31048489
    [Google Scholar]
  89. Bhattacharyya S. Crain C.R. Goldberg B. Gaiha G.D. Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development. Curr. Opin. HIV AIDS 2023 18 5 257 263 10.1097/COH.0000000000000812 37535040
    [Google Scholar]
  90. Agrati C. Castilletti C. Battella S. Cimini E. Matusali G. Sommella A. Sacchi A. Colavita F. Contino A.M. Bordoni V. Meschi S. Gramigna G. Barra F. Grassi G. Bordi L. Lapa D. Notari S. Casetti R. Bettini A. Francalancia M. Ciufoli F. Vergori A. Vita S. Gentile M. Raggioli A. Plazzi M.M. Bacchieri A. Nicastri E. Antinori A. Milleri S. Lanini S. Colloca S. Girardi E. Camerini R. Ippolito G. Vaia F. Folgori A. Capone S. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. NPJ Vaccines 2022 7 1 111 10.1038/s41541‑022‑00531‑8 36153335
    [Google Scholar]
  91. Lanini S Capone S Antinori A Milleri S Nicastri E Camerini R GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Sci. Transl. Med. 2022 14 627 eabj1996
    [Google Scholar]
  92. Capone S. Fusco F.M. Milleri S. Borrè S. Carbonara S. Lo Caputo S. Leone S. Gori G. Maggi P. Cascio A. Lichtner M. Cauda R. Dal Zoppo S. Cossu M.V. Gori A. Roda S. Confalonieri P. Bonora S. Missale G. Codeluppi M. Mezzaroma I. Capici S. Pontali E. Libanore M. Diani A. Lanini S. Battella S. Contino A.M. Piano Mortari E. Genova F. Parente G. Dragonetti R. Colloca S. Visani L. Iannacone C. Carsetti R. Folgori A. Camerini R. Ziviani L. Malescio F. Turrini I. Lawlor R. Romano A. Nunziata M. Armato S. Mazzeo N. Carleo M.A. Dell’Isola C. Pisapia R. Pontarelli A. Olivani A. Grasselli S. Laccabue D. Leoni M.C. Paolillo F. Mancini A. Ruaro B. Confalonieri M. Salton F. Mancarella G. Marocco R. De Masi M. Belvisi V. Lamonica S. Cingolani A. Seguiti C. Brambilla P. Ferraresi A. Lupi M. Ludovisi S. Renisi G. Massafra R. Pellicciotta M. Armiento L. Vimercati S. Piacenza M. Bonfanti P. Columpsi P. Cazzaniga M.E. Rovelli C. Ceresini M. Previtali L. Trentini L. Alcantarini C. Rugge W. Biffi S. Poletti F. Rostagno R. Moglia R. De Negri F. Fini E. Cangialosi A. Bruno S.R. Rizzo M. Niglio M. Stritto A.D. Matano A. Petruzziello A. Valsecchi P. Pieri T. Altamura M. Calamo A. Giannelli A. Menolascina S. Di Bari S. Mauro V. Aronica R. Segala D. Cultrera R. Sighinolfi L. Abbott M. Gizzi A. Marascia F.G. Valenti G. Feasi M. Bobbio N. Del Puente F. Nicosia A. Frascà M. Mazzoleni M. Garofalo N. Ammendola V. Grazioli F. Napolitano F. Vitelli A. Marcellini V. COVITAR study group GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. Cell Rep. Med. 2023 4 6 101084 10.1016/j.xcrm.2023.101084 37315558
    [Google Scholar]
  93. McMahon J.H. Hoy J.F. Kamarulzaman A. Bekker L.G. Beyrer C. Lewin S.R. Leveraging the advances in HIV for COVID-19. Lancet 2020 396 10256 943 944 10.1016/S0140‑6736(20)32012‑2 33010825
    [Google Scholar]
  94. Fauci A.S. The story behind COVID-19 vaccines. Science 2021 372 6538 109 10.1126/science.abi8397 33833099
    [Google Scholar]
  95. Feinberg MB Russell ND Shattock RJ Youngdahl KB The importance of partnerships in accelerating HIV vaccine research and development. J. Int. AIDS Soc. 2021 24 Suppl 7 25824
    [Google Scholar]
  96. Gray G.E. Bekker L.G. Laher F. Malahleha M. Allen M. Moodie Z. Grunenberg N. Huang Y. Grove D. Prigmore B. Kee J.J. Benkeser D. Hural J. Innes C. Lazarus E. Meintjes G. Naicker N. Kalonji D. Nchabeleng M. Sebe M. Singh N. Kotze P. Kassim S. Dubula T. Naicker V. Brumskine W. Ncayiya C.N. Ward A.M. Garrett N. Kistnasami G. Gaffoor Z. Selepe P. Makhoba P.B. Mathebula M.P. Mda P. Adonis T. Mapetla K.S. Modibedi B. Philip T. Kobane G. Bentley C. Ramirez S. Takuva S. Jones M. Sikhosana M. Atujuna M. Andrasik M. Hejazi N.S. Puren A. Wiesner L. Phogat S. Diaz Granados C. Koutsoukos M. Van Der Meeren O. Barnett S.W. Kanesa-Thasan N. Kublin J.G. McElrath M.J. Gilbert P.B. Janes H. Corey L. HVTN 702 Study Team Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults. N. Engl. J. Med. 2021 384 12 1089 1100 10.1056/NEJMoa2031499 33761206
    [Google Scholar]
  97. Gray G.E. Mngadi K. Lavreys L. Nijs S. Gilbert P.B. Hural J. Hyrien O. Juraska M. Luedtke A. Mann P. McElrath M.J. Odhiambo J.A. Stieh D.J. van Duijn J. Takalani A.N. Willems W. Tapley A. Tomaras G.D. Van Hoof J. Schuitemaker H. Swann E. Barouch D.H. Kublin J.G. Corey L. Pau M.G. Buchbinder S. Tomaka F. Allagappen J. Andriesen J. Ayres A. Bekker L-G. Borremans C. Brumskine W. Chilengi R. Dubula T. Garrett N. Gelderblom H. Gill K. Hoosain Z. Hosseinipour M. Hutter J. Inambao M. Innes C. Kilembe W. Kotze P. Kotze S. Laher F. Laszlo I. Lazarus E. Malahleha M. Mathebula M. Matoga M. McClennen R. Mda P. Meerts P. Naicker V. Naidoo L. Philip T. Pitsi A. Scheppler L. Sopher C. Takuva S.G. Viegas E. Weijtens M. Yuan O. Imbokodo/HVTN 705/HPX2008 Study Group Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect. Dis. 2024 24 11 1201 1212 10.1016/S1473‑3099(24)00358‑X 39038477
    [Google Scholar]
  98. Pan J. Zhong Y. Young S. Niezink N.M.D. Collaboration on evidence synthesis in Africa: A network study of growing research capacity. Health Res. Policy Syst. 2021 19 1 126 10.1186/s12961‑021‑00774‑2 34538255
    [Google Scholar]
  99. Breman J.G. Heymann D.L. Lloyd G. McCormick J.B. Miatudila M. Murphy F.A. Muyembé-Tamfun J.J. Piot P. Ruppol J.F. Sureau P. van der Groen G. Johnson K.M. Discovery and description of ebola zaire virus in 1976 and relevance to the west african epidemic during 2013–2016. J. Infect. Dis. 2016 214 S93 S101 10.1093/infdis/jiw207 27357339
    [Google Scholar]
  100. Kasprowicz V.O. Chopera D. Waddilove K.D. Brockman M.A. Gilmour J. Hunter E. Kilembe W. Karita E. Gaseitsiwe S. Sanders E.J. Ndung’u T. African-led health research and capacity building- is it working? BMC Public Health 2020 20 1 1104 10.1186/s12889‑020‑08875‑3 32664891
    [Google Scholar]
  101. Kasprowicz V.O. Waddilove K.D. Chopera D. Khumalo S. Harilall S. Wong E.B. Karita E. Sanders E.J. Kilembe W. Gaseitsiwe S. Ndung’u T. Developing a diversity, equity and inclusion compass to guide scientific capacity strengthening efforts in Africa. PLOS Glob. Public Health 2023 3 12 0002339 10.1371/journal.pgph.0002339 38117812
    [Google Scholar]
/content/journals/chr/10.2174/011570162X364991250710044947
Loading
Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development
Bentham Science Publishers ; https://doi.org/10.2174/011570162X364991250710044947
/content/journals/chr/10.2174/011570162X364991250710044947
/content/journals/chr/10.2174/011570162X364991250710044947
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: antiretroviral therapy ; HIV epidemic ; AIDS Vaccine Discovery ; CD8 T cell responses ; pre-exposure prophylaxis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test